Edwards Lifesciences Available for sale investments decreased by 5.3% to $1.23B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 49.4%, from $824.00M to $1.23B. Over 5 years (FY 2020 to FY 2025), Available for sale investments shows an upward trend with a 6.8% CAGR.
An increase reflects a larger investment portfolio size, while fluctuations in value indicate changes in market interest rates and credit spreads.
These are debt securities that are not classified as held-to-maturity or trading securities, representing investments th...
Common in insurance portfolios to balance yield generation with liquidity requirements.
other_available_for_sale_securities_debt_securities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.15B | $1.40B | $2.18B | $1.84B | $1.64B | $1.64B | $1.48B | $1.31B | $1.18B | $1.02B | $898.70M | $749.80M | $521.60M | $894.20M | $1.02B | $824.00M | $836.70M | $1.18B | $1.30B | $1.23B |
| QoQ Change | — | +22.6% | +55.4% | -15.9% | -10.5% | -0.2% | -9.7% | -11.6% | -9.5% | -13.8% | -11.9% | -16.6% | -30.4% | +71.4% | +14.2% | -19.3% | +1.5% | +40.6% | +10.5% | -5.3% |
| YoY Change | — | — | — | — | +43.4% | +16.7% | -32.2% | -28.7% | -27.9% | -37.8% | -39.3% | -42.7% | -56.0% | -12.4% | +13.6% | +9.9% | +60.4% | +31.6% | +27.3% | +49.4% |